| | 1622848-92-3 Basic information More.. |
| Product Name: | GSK2982772 | | Synonyms: | (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;5184;GSK2982772;RIP1 inhibitor GS2982772;CS-2502;(S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROBENZO[B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CAR;GSK 2982772;GSK-2982772;1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxo-1,5-benzoxazepin-3-yl]- | | CAS: | 1622848-92-3 | | MF: | C20H19N5O3 | | MW: | 377.4 | | EINECS: | | | Mol File: | 1622848-92-3.mol |  |
Use
Harris, P. A., et al. Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry 60.4(2017):1247-1261.
Jeong, Jae Uk, et al. Synthesis of ( S )-3-amino-benzo[ b ][1,4]oxazepin-4-one via Mitsunobu and S N Ar reaction for a first-in-class RIP1 kinase inhibitor GSK2982772 in clinical trials. Tetrahedron Letters 58.23(2017):2306-2308.
- GSK2982772
-
- US $1.00-1.00 / KG
- 2019-09-02
- CAS:1622848-92-3
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1lg; 2kg; 5kg; 10kg; 100kg
|
|
1622848-92-3
Recommend Suppliers |
|